Rezera

News

Inflammation-focused Rezera sets terms for IPO

Rezera, formerly known as NodThera, has announced the terms of its planned IPO, hoping to raise upwards of $200m for its NLRP3 inhibitor pipeline.

News

Ex-Jazz, Sunesis exec Swisher takes over at NodThera

Anglo-US biotech NodThera has named former Jazz Pharma executive Dan Swisher as its new chief executive, replacing Alan Watt, who will take on the dual roles of president

News

NodThera raises $55m in Series B round to trial inflammatory...

The Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory diseases drugs for clinical trials.

Inflammation-focused Rezera sets terms for IPO

Ex-Jazz, Sunesis exec Swisher takes over at NodThera

NodThera raises $55m in Series B round to trial inflammatory...

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks